...
首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Synthesis and carbonic anhydrase I, II, IV and XII inhibitory properties of N-protected amino acid – sulfonamide conjugates
【24h】

Synthesis and carbonic anhydrase I, II, IV and XII inhibitory properties of N-protected amino acid – sulfonamide conjugates

机译:N-保护的氨基酸-磺酰胺结合物的合成及其碳酸酐酶I,II,IV和XII的抑制特性

获取原文
           

摘要

Abstract N-protected amino acids (Gly, Ala and Phe protected with Boc and Z groups) were reacted with sulfonamide derivatives, leading to the corresponding N-protected amino acid–sulfonamide conjugates. The carbonic anhydrase (CA, EC 4.2.1.1) inhibitory activity of the new compounds was assessed against four human (h) isoforms, hCA I, hCA II, hCA IV and hCA XII. Among them, hCA II, IV and XII are antiglaucoma drug targets, being involved in aqueous humor secretion within the eye. Low nanomolar inhibition was measured against all four isoforms with the 20 reported sulfonamides, but no selective inhibitory profiles, except for some CA XII-selective derivatives, were observed. hCA I, II and XII were generally better inhibited by sulfonamides incorporating longer scaffolds and Gly/Ala, whereas the best hCA IV inhibitors were homosulfanilamide derivatives, incorporating Phe moieties. The amino acid–sulfonamide conjugates show good water solubility and effective hCA II, IV and XII inhibition, and may be considered as interesting candidates for antiglaucoma studies.
机译:摘要N-保护的氨基酸(Gly,Ala和Phe被Boc和Z基团保护)与磺酰胺衍生物反应,生成相应的N-保护的氨基酸-磺酰胺共轭物。评估了新化合物的碳酸酐酶(CA,EC 4.2.1.1)对四种人(h)异构体hCA I,hCA II,hCA IV和hCA XII的抑制活性。其中,hCA II,IV和XII是抗青光眼药物的靶标,参与眼内房水的分泌。使用20种已报告的磺酰胺类药物,对所有四种同工型均测得了较低的纳摩尔抑制作用,但未观察到除某些CA XII选择性衍生物外的选择性抑制曲线。 hCA I,II和XII通常被掺入较长支架和Gly / Ala的磺酰胺更好地抑制,而最佳的hCA IV抑制剂是掺入Phe部分的高磺胺衍生物。氨基酸-磺酰胺结合物显示出良好的水溶性和有效的hCA II,IV和XII抑制作用,可能被认为是抗青光眼研究的有趣候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号